RAPS Releases New Edition of Essential US Regulatory Affairs Reference Book
The Regulatory Affairs Professionals Society (RAPS) has published the updated, eighth edition of its essential regulatory reference book, Fundamentals of US Regulatory Affairs. The book provides extensive information on current regulatory requirements from FDA, and other state and federal agencies.
Fundamentals of US Regulatory Affairs, Eighth Edition includes updated regulatory information pertaining to pharmaceuticals, medical devices, biologics and other healthcare products intended for the US market. New content for this edition includes coverage of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, and new chapters on pharmacovigilance, medical foods, crisis management, health technology assessment, and companion diagnostics. A chapter on Prescription Drug Product Submissions was revised by reviewers from FDA’s Center for Drug Evaluation and Research, and is publicly available online.
“This book is an outstanding overview of the drug, biologic and device regulatory pathways and requirements. It is thorough and clearly written,” said Edward Tabor, MD, vice president, regulatory affairs North America, Fresenius Kabi, and a member of RAPS’ board of directors. “Not only is it useful for anyone who wants to learn about the regulatory process; it also provides a ready reference for experienced regulatory professionals.”
In addition to being useful to professionals new to US regulatory affairs or as handy reference, many professionals preparing for the US Regulatory Affairs Certification (RAC) exam cite Fundamentals as an indispensable RAC study tool. It also has been used as a training resource at many healthcare organizations and is a mandatory text for university-level courses.
Fundamentals of US Regulatory Affairs, Eighth Edition is available both in print and as an e-book for $249.95 with free shipping for RAPS members or $309.95, plus shipping, for nonmembers.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance